Bicara Therapeutics Inc Dossier - Source-backed chat

Bicara Therapeutics Inc

BCAXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.18

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $18.61Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.2B

Enterprise Value $1.1B

Shares Outstanding 66.2M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Bicara Therapeutics is a clinical-stage biotechnology company focused on developing transformative bifunctional therapies for solid tumors. Its lead asset, ficerafusp alfa, is a first-in-class bifunctional EGFR/TGF-̢ antibody showing highly differentiated clinical efficacy in HPV-negative head and neck squamous cell carcinoma (HNSCC). Backed by a robust cash position of $539.8 million following a successful Q1 2026 public offering, the company has a secure cash runway extending into 1H 2029. This financial strength fully funds the pivotal Phase 2/3 FORTIFI-HN01 trial through its highly anticipated mid-2027 interim analysis, presenting a compelling risk-reward profile for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$33.38

High · most bullish analyst$45.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.0015%

The pivotal FORTIFI-HN01 trial experiences enrollment delays or fails to replicate the strong efficacy seen in earlier Phase 1b cohorts during the mid-2027 interim analysis. Safety concerns, such as severe toxicities related to systemic TGF-̢ inhibition or EGFR-directed side effects, emerge. The alternate dosing study fails to show a favorable safety/convenience profile, and signal-seeking trials in colorectal cancer show no meaningful clinical activity, severely limiting the asset's market potential.

Base CaseCentral scenario

$33.3850%

Matches the consensus mean

FORTIFI-HN01 trial completes substantial enrollment by the end of 2026, leading to a successful interim analysis in mid-2027 that meets primary endpoints. The company initiates its planned loading/maintenance dosing study in Q3 2026 to optimize long-term administration. Efficacy remains consistent with Phase 1b results (54% ORR, 21.3 months median OS), positioning the drug for a standard or accelerated regulatory filing. Cash runway remains secure into 2029.

Bull CaseUpside scenario

$45.0035%

Ficerafusp alfa achieves outstanding interim results in the FORTIFI-HN01 trial in mid-2027, demonstrating clear superiority over pembrolizumab standard of care. The FDA grants accelerated approval, and the company successfully launches the drug in the U.S. with the help of newly hired commercial leadership. Pipeline expansion into colorectal cancer (mCRC) and other solid tumors yields positive signal-seeking data, unlocking blockbuster potential.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly differentiated, first-in-class dual-action mechanism targeting both EGFR and the immunosuppressive TGF-̢ tumor microenvironment.
Exceptional clinical data in 1L HPV-negative HNSCC, showing a median overall survival of 21.3 months (more than double the standard of care pembrolizumab monotherapy).
Robust balance sheet with $539.8 million in cash, cash equivalents, and marketable securities, providing a runway into the first half of 2029 and eliminating near-term dilution risk.

Key Investment Risks

High clinical development risk as a single-asset-reliant clinical-stage biotech, with success heavily dependent on the FORTIFI-HN01 trial.
Potential regulatory hurdles or delays in aligning with the FDA on optimal dosing regimens and trial designs.
Intense competition in the oncology space from established immunotherapies and other emerging bifunctional platforms.

Thesis Invalidation Triggers

Failure of the FORTIFI-HN01 trial to meet its primary endpoints of progression-free survival or overall survival during the mid-2027 interim analysis.
Unexpected severe adverse events or toxicities that lead to clinical holds or restrict the commercial viability of ficerafusp alfa.
Significant delays in patient enrollment for the pivotal Phase 3 trial, pushing back the expected data readouts beyond 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.